Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Enzomenib might be the most promising agent so far, on a cross-trial basis.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
And the company might one day follow Galapagos into decentralised manufacturing.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
